Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space At this year's EURETINA Congress, we caught up with Enrico Borrelli, MD, FEBO, during a break from his busy schedule. He is ...

Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina ...

TIME Magazine named Zack Dvey-Aharon, PhD, to the 2024 TIME100 AI list. This annual list highlights the 100 most influential individuals in artificial intelligence (AI). According to a press release 1 ...

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1. Priovant Therapeutics has enrolled the first patients in the CLARITY Phase 3 study evaluating brepocitinib in ...

At this year's European Society of Retina Specialists (EURETINA) meeting, a number of keynote speakers presented on a wide array of topics. Kyoko Ohno-Matsui, MD, PhD, delivered the Euretina Lecture ...

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab At this year's EURETINA Congress, Timothy L Jackson PhD, MB ChB ...

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings ...

Inflammasome Therapeutics has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug, K9. Inflammasome Therapeutics has completed enrollment of a Phase I ...